12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GM-CSF-adjuvanted DNA/MVA vaccine: Phase I start

Next month, GeoVax will begin a U.S. Phase I trial to evaluate its GM-CSF-adjuvanted DNA/MVA vaccine. The trial is sponsored by the NIH's National Institute of Allergy...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >